Serum Amyloid Protein (nonspecific Subtype) as a Drug Target and Biomarker

Target Name: Serum amyloid protein

NCBI ID: P40583

Serum amyloid protein

Other Name(s): Serum amyloid | SA | SAA

Serum Amyloid Protein (nonspecific Subtype) as a Drug Target and Biomarker

Abstract

Serum amyloid protein (nonspecific subtype) (Serum amyloid) is a highly aggregating protein that has been identified as a potential drug target and biomarker for various diseases, including Alzheimer's disease, Parkinson's disease, and other neurodegenerative disorders. This article reviews the current understanding of Serum amyloid and its potential as a drug target, as well as its potential as a biomarker for these disorders.

Serum amyloid protein (nonspecific subtype) (Serum amyloid) is a highly aggregating protein that is synthesized in the liver and is involved in various physiological processes, including immune response and inflammation. However, abnormally aggregated Serum amyloid has been implicated in the development and progression of various neurodegenerative disorders, including Alzheimer's disease, Parkinson's disease, and other neurodegenerative disorders.

Drug Target Potential

Serum amyloid has been identified as a potential drug target due to its aggregating properties and its involvement in the development and progression of neurodegenerative disorders. Several studies have shown that inhibiting Serum amyloid aggregation can lead to improved cognitive function and reduced neurodegeneration in animal models of neurodegenerative disorders. Additionally, there are human clinical trials underway to evaluate Serum amyloid as a potential drug target for neurodegenerative disorders.

Biomarker Potential

Serum amyloid has also been identified as a potential biomarker for neurodegenerative disorders. The presence of abnormally aggregated Serum amyloid in the brains of individuals with neurodegenerative disorders has been confirmed using various techniques, including post-mortem brain analysis and neuroimaging techniques. Additionally, studies have shown that Serum amyloid levels are significantly increased in individuals with neurodegenerative disorders, which could be used as a biomarker for these disorders.

Current Treatment Options

Current treatment options for neurodegenerative disorders are limited and often ineffective in preventing the progression of these disorders. While there are some disease-modifying treatments available, there is a significant need for new and more effective treatments.

Conclusion

Serum amyloid protein (nonspecific subtype) (Serum amyloid) has been identified as a potential drug target and biomarker for various neurodegenerative disorders. While further research is needed to fully understand its potential, its abnormal aggregating properties and its involvement in the development and progression of neurodegenerative disorders make it a promising target for future research and development.

Protein Name: Serum Amyloid Protein (nonspecified Subtype)

The "Serum amyloid protein Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about Serum amyloid protein comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets